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OBJECTIVES: Mesenchymal stem cells (MSCs) are potentially ideal for type 2 diabetes treatment, owing to their
multidirectional differentiation ability and immunomodulatory properties. Here we investigated whether the
stem cells from human exfoliated deciduous teeth (SHED) in combination with hyperbaric oxygen (HBO) could
treat type 2 diabetic rats, and explored the underlying mechanism.
METHODS: SD rats were used to generate a type 2 diabetes model, which received stem cell therapy, HBO
therapy, or both together. Before and after treatment, body weight, blood glucose, and serum insulin, blood
lipid, pro-inflammatory cytokines (tumor necrosis factor-alpha and interleukin-6), and urinary proteins were
measured and compared. After 6 weeks, rats were sacrificed and their organs were subjected to hematoxylin
and eosin staining and immunofluorescence staining for insulin and glucagon; apoptosis and proliferation were
analyzed in islet cells. Structural changes in islets were observed under an electron microscope. Expression levels
of Pdx1, Ngn3, and Pax4 mRNAs in the pancreas were assessed by real-time quantitative polymerase chain
reaction (RT-qPCR).
RESULTS: In comparison with diabetic mice, those treated with the combination or SHE therapy showed
decreased blood glucose, insulin resistance, serum lipids, and pro-inflammatory cytokines and increased body
weight and serum insulin. The morphology and structure of pancreatic islets improved, as evident from an
increase in insulin-positive cells and a decrease in glucagon-positive cells. Terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling (TUNEL) staining of islet cells revealed the decreased apoptosis index, while
Ki67 and proliferating cell nuclear antigen staining showed increased proliferation index. Pancreatic expression
of Pdx1, Ngn3, and Pax4 was upregulated.
CONCLUSION: SHED combined with HBO therapy was effective for treating type 2 diabetic rats. The underlying
mechanism may involve SHED-mediated increase in the proliferation and trans-differentiation of islet b-cells and
decrease in pro-inflammatory cytokines and apoptosis of islets.
KEYWORDS: Type 2 Diabetic Rats; SHED; Stem Cell Therapy; Hyperbaric Oxygen Therapy; Immunoregulation.
’ INTRODUCTION
Diabetes is the 11th most common cause of disability
worldwide, and serves as a high risk factor for cardiovas-
cular disease. According to the International Diabetes
Federation (IDF) (1), more than 425 million people world-
wide had diabetes in 2017 and this number is expected to
increase to 625 million by 2045. In 2017 alone, diabetes and
its complications killed more than 4 million people and were
associated with a treatment cost of $727 billion. Diabetes has
emerged as a serious global and social public health problem
and is a heavy social and economic burden. Type 2 diabetes
(T2DM) accounts for about 90 percent of all diabetes cases.
It is mainly caused by insulin resistance and islet cell
dysfunction. The current medicines and treatment regimens
are ineffective in preventing the spread and development of
diabetes and its complications. Stem cell and regenerative
medicine technology has exploited the multi-directional
differentiation, autocrine and paracrine, immune regulation,
and other characteristics of mesenchymal stem cells (MSCs)DOI: 10.6061/clinics/2020/e1656
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to repair or replace the function of a damaged pancreatic
tissue, thereby raising our hopes for diabetes treatment.
Dental pulp MSCs have been studied in animal models of
different diseases (2), including systemic lupus erythemato-
sus, ischemic brain injury, spinal cord injury, and muscular
atrophy. Stem cells from human exfoliated deciduous teeth
(SHED) were shown to differentiate into insulin-secreting
cells in vitro (3), and may be potentially useful for the
treatment of glucose metabolic disorders. Hyperbaric oxygen
(HBO) therapy could increase the concentration of nitric
oxide synthase, and promote mobilization of stem cells and
release of endothelial progenitor cells (4). These cells may
migrate to inflammatory or injured sites in the presence of
inflammatory factors or chemokines (5). Oxygen regulation
may also promote the maturation of pancreatic progenitor
cells (6), and HBO may promote the survival and growth of
transplanted islet cells by improving local oxygen supply (7).
Therefore, the combination of stem cells and HBO therapy
may play a plausible synergistic role in the therapy for
diabetes (8,9).
’ MATERIALS AND METHODS
Animal model and groups
All animal experiments were approved by the Ethics Com-
mittee for Medical Laboratory Animal Sciences of Changhai
Hospital of Shanghai (approval No. 201700632). Male Sprague
Dawley (SD) rats weighing 90–100 g were obtained from the
experimental animal center of Naval Medical University. All
rats were housed at 25oC±1oC on a 12h light/dark cycle and
fed ad libitum for 1 week before study inception. Animals were
then fed with a high-fat diet (40% fat, 40% carbohydrate, and
20% protein) for 8 weeks, and a diabetic rat model was gene-
rated through a single intraperitoneal injection of streptozo-
tocin (STZ, Sigma, USA) at 30 mg/kg body weight in sodium
citrate buffer (pH 4.2) after overnight fasting. Blood glucose
(BG) concentration was measured using a drop of tail capil-
lary blood by a glucometer. Fasting blood glucose (FBG)
X8.3mmol/L after 3 days, or BG 2h post oral glucose tolerance
test (OGTT) after 3 days or a stable non-fasting BG concentra-
tionX11.1 mmol/L for 7 days, were indicative of the successful
establishment of the T2DM rat model (10).
T2DM rats were randomly divided into four groups as
follows: Stem cell therapy group (SC, n=6), HBO therapy
group (HBO, n=6), stem cells combined with HBO group
(SC+HBO, n=6), and diabetes control group (DM, n=6).
Normal rats on normal diet were set as the normal control
group (NC, n=6).
Stem cell therapy
SHED from P4 to P6 were supplied free of charge by CAR-
T (Shanghai) Biotechnology Co., Ltd, at a density of 1107
cells/mL. The expression of surface marker CD90 on MSCs
was analyzed (495%) by flow cytometry; CD34 and HLA-
DR expression was low but could be detected in about 0.5%
cells. Rats from SC and SC+HBO groups were transfused
with 0.5 mL SHED through their caudal veins in the first and
third week (twice), while rats from the other groups were
transfused with an equal volume of sodium chloride.
HBO therapy
HBO therapy was performed in the diving medical
laboratory of the department of marine medicine of Naval
Medical University. Rats from HBO and SC+HBO groups
received HBO therapy daily for a total of 28 sessions. Animals
were exposed to an atmospheric pressure of 2 at an oxygen
concentration of X85% for 1h daily in an HBO chamber
(DWC-1000-2100, No. 701 Yangyuan Medical Oxygen Cham-
ber Factory, Shanghai). The HBO chamber was first filled
with pure oxygen for 3 min and then gradually pressu-
rized for 10 min from 0 to 0.1 MPa. The pressure in the
chamber was maintained at 0.1 MPa for 1h, after which the
chamber was gradually decompressed for 15 min from 0.1 to
0 MPa.
Biochemical assays and enzyme-linked
immunosorbent assay (ELISA)
Rats were sacrificed after 6 weeks of therapy. During treat-
ment period, body weight of rats was measured every week
and OGTT was performed every 2 weeks following over-
night fasting. Glucose was intragastrically administered
(2 g/kg body weight), and BG and serum insulin levels were
detected at 0, 30, 60, 90, and 120 min. BG level was measured
by a glucometer (Rightest GM300, Huaguang Biotech Co.
LTD, Taiwan) using glucose oxidase assay. Serum insulin
levels were measured using an ELISA (CUSABIO, Wuhan),
while serum lipid (total cholesterol [TC], triglyceride [TG],
low-density lipoprotein cholesterol [LDL-C], and high-
density lipoprotein cholesterol [HDL-C]) and 24h urinary
protein levels were measured using a fully automatic bio-
chemical analyzer (Chemray 240, Rayto Life and Analytical
Sciences Co., Ltd, Shenzhen) according to the manufacturer’s
protocols. Serum interleukin (IL)-6 and tumor necrosis factor
(TNF)-a levels were measured using rat ELISA kits (Lianke
Bio, Hangzhou). Area under the curves (11) for BG or insu-
lin were calculated as follows: AUCBG 0-120 (mmol/L  h) =
([BG00+BG300] 30/60)/2 + ([BG300+BG600] 30/60)/2 +
([BG600+BG900] 30/60)/2 + ([BG900+BG1200] 30/60)/2;
AUCINS0-120 (nIU/mL h) = ([INS00+INS300] 30/60)/2 +
([INS300+INS600] 30/60)/2 + ([INS600+INS900] 30/60)/
2+ ([INS900+INS1200] 30/60)/2. Homeostasis model assess-
ment of insulin resistance (HOMA-IR) was calculated as
follows: HOMA-IR = INS00 (mU/mL)  BG00 (mmol/L)/22.5.
Histopathological analysis
Sections of pancreas samples were stained with hematox-
ylin and eosin (H&E) and examined under a light micro-
scope. Ultrastructure of intracellular organelles in b-cells was
detected by transmission electron microscopy (HT7700,
HITACHI), and particles were counted by Image-pro Plus
6.0 (IPP, Media Cybernetics, Inc.) software.
Insulin and glucagon in pancreatic islets were analyzed
by immunohistochemical staining using insulin mouse mAb
and glucagon rabbit mAb, respectively (Wuhan Servicebio
technology), as well as by immunofluorescence staining using
sheep anti-rabbit IgG-fluorescein isothiocyanate (FITC; Abcam),
sheep anti-mouse IgG-CY3 (Sigma), and 40,6-diamidino-2-
phenylindole (DAPI; Sigma). Staining was observed by
fluorescence microscopy (DP80, Olympus bx-53). Image-pro
Plus 6.0 (IPP, Media Cybernetics, Inc.) software was used to
count positively stained cells, and integrated optical density
(IOD) of positive staining for insulin or glucagon was
calculated and analyzed in immunofluorescence sections of
the pancreas. Mean optical density (MOD) was calculated
(MOD = IOD SUM/area) and compared. After 6 weeks of
therapy, three islets from each pancreas tissue were analyzed
for MOD of insulin and glucagon.
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The serial pancreatic sections were evaluated for apoptotic
cells in islets by terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling (TUNEL) assay (In Situ
Cell Death Detection Kit, Roche), while proliferative cells
were detected with proliferating cell nuclear antigen (PCNA)
and Ki67 (rabbit mAbs for anti-PCNA and anti-Ki67; Abcam).
Apoptosis index (AI) and proliferation index (PI) were cal-
culated as follows: AI = Number of apoptotic cells/(Number
of apoptotic cells + Number of normal cells); PI = Number
of proliferative cells/(Number of proliferative cells + Num-
ber of normal cells). After 6 weeks of therapy, three islets
from rat pancreas were analyzed for AI and PI.
Real-time quantitative polymerase chain reaction
(RT-qPCR)
The mRNA expression levels of Pdx1, Ngn3, and Pax4 in
the pancreas were quantified by RT-qPCR using the SYBR
Green method. Rats were sacrificed and their pancreas were
excised and lysed using Trizol reagent (Invitrogen) to extract
RNA. Total RNAwas identified and measured using a spec-
trophotometer (Nanodrop 1000, USA). The genes were ampli-
fied using a 96-well gradient PCR amplification apparatus
(ABI Veriti, USA). Target genes were quantified by a real-time
detector (Roche LightCyclers 480II, Switzerland). Glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) was used as
the reference gene. PCR primers were synthesized by Sangon
Biotech Co. Ltd. Shanghai. PrimeScript reverse-transcription
kit and Premix ExTaq were obtained from Takara, Japan.
Primer sequences were designed using the Oligo Primer
Analysis Software (Version: 7.60, Wojciech & Piotr Rychlik,
USA), and their specificity was verified on the website of
Primer-blast.
Oligo Name: Pdx1 Sequence (50 to 30)
Forward primer GCACAAGAGCCAGTTGGGTA Plus
Reverse primer ATTGTCCTCAGTTGGGAGCC Minus
Product length 175
Oligo Name: Pax4
Forward primer ACAGATGCCAGGTGCTTCTC Plus
Reverse primer ATGATGCACAGGATGGGTGG Minus
Product length 292
Oligo Name: Ngn3
Forward primer ATGACAGAAGGGGCCAAAGG Plus







All measurement data are expressed as the mean ± stan-
dard deviation. Before analysis, the data were tested for nor-
mality of distribution using the Kolmogorov-Smirnov test.
For normally distributed data, differences between groups
were analyzed using the least-significant difference test.
A value of po0.05 was considered statistically significant.
SPSS 22.0 (IBM) was used for statistical analyses.
’ RESULTS
General conditions and measurement indicators
All rats were included for analysis (n=6 in each group).
After treatment, the mental state of the rats from SC+HBO
and SC groups was better than that of rats from DM group.
Water consumption and urination significantly reduced and
body weights increased for the rats from SC+HBO and SC
groups (Figure 1A). Further, BG level gradually decreased
(Figure 1B), serum insulin secretion increased (Figure 1C),
and HOMA-IR (Figure 1D), serum LDL-C and TG (Figure 2
A), 24h urinary protein (Figure 2B), and serum TNF-a and
IL-6 (Figure 2C, 2D) reduced in these groups as compared
with those in DM group. The therapeutic effect in SC+HBO
group appeared earlier than that in SC group.
Histopathology
Pancreatic islet morphology. After 6 weeks of therapy,
the morphology of pancreatic islets was relatively intact and
the number of inflammatory cells decreased in H&E-stained
sections from SC+HBO and SC groups (Figure 3A). Electron
microscopy revealed the improvement in the nuclear mem-
brane integrity of organelles and the significant increase in
secretory particles for SC+HBO and SC groups as compared
with those for DM group (Figure 3B).
Immunofluorescence staining for insulin or glucagon
in pancreatic islets. After the 6-week therapy, the MOD
for insulin immunofluorescence staining in pancreatic islets
was significantly higher for SC+HBO and SC groups than
that for DM group, while the MOD values for glucagon in
SC+HBO and SC groups were lower than the value for DM
group (Figure 4A, 4B).
Apoptosis and proliferation of pancreatic islet cells.
After 6 weeks of therapy, apoptosis significantly reduced and
proliferation significantly increased for the islet cells from
SC+HBO and SC groups as compared with those for the
islets cells from DM group (Figure 5A, 5B).
RT-qPCR. The quantitative expression of pancreatic Pdx1,
Pax4, and Ngn3 mRNAs was analyzed after 6 weeks of
therapy. All six rats from each group were used for RT-qPCR.
Gene expression was significantly upregulated in the sam-
ples from SC+HBO and SC groups as compared with that in
samples from DM group. The expression of these genes in
SC+HBO group was higher than that reported in SC group
(Figure 6).
’ DISCUSSION
In 2003, Professor Shi Songtao discovered dental pulp stem
cells in his 6-year-old daughter’s deciduous teeth and named
them as SHED. These cells originate from the cranial neural
crest and express surface molecules or antigens for MSCs
such as CD29, CD44, CD73, CD90, CD105, CD166, STRO-1,
CD146, and stage-specific embryonic antigen 4 (SSEA4) (12).
Differentiation may be induced in some cell types, including
adipocytes, neurons, chondrocytes, and MSCs, using specific
stimulation conditions (13-15). Unlike the umbilical cord or
cord blood stem cells that need to be extracted at birth, dental
pulp stem cells may be harvested from either deciduous or
permanent teeth and easily collected without any risk of com-
plications (16). Humans bear 20 deciduous teeth that even-
tually fall off. Hence, there is no ethical issue involved in their
collection. SHED exhibit high proliferation and differentiation
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Figure 1 - Body weight and glucose metabolism indices of rats. A. Body weight: After 3 weeks of therapy, the body weights of the rats
from the SC+HBO group were higher than those of the rats from the DM group. After 5 weeks, the body weights of the rats from the
SC+HBO group were higher than those of the rats from the HBO group. After 6 weeks, the SC group rats had higher body weight than
the DM group rats. B. AUC of BG by OGTT: After 2 weeks of therapy, the AUC for the rats from the SC+HBO group was lower than that
for the rats from the DM group. The AUC value decreased for SC group rats as compared with that for DM group rats after 4 weeks. The
AUC of SC+HBO group rats was lower than that of HBO group rats. C. AUC of INS by OGTT: After 4 weeks, the AUC started to increase
for the rats from SC+HBO and SC groups as compared with that for the rats from DM group. D. HOMA-IR: After 4 weeks, the HOMA-IR
for SC+HBO and SC group rats was lower than that for DM group rats. *po0.05, **po0.01 vs DM group, Wpo0.05 vs HBO group.
::po0.01 vs each of the other four groups.
Figure 2 - Blood lipid, proinflammatory cytokine, and urine protein of rats. A. Blood lipid after 6 weeks of therapy: Serum TG and LDL
levels were higher in SC+HBO, SC, and HBO groups than those in the DM group. B. 24h urine protein: After 4 weeks, urine protein
levels began to decrease in SC+HBO and SC groups as compared with those in DM group. C. Serum TNF-a: After 2 weeks, serum TNF-a
levels began to decrease in SC+HBO and SC groups as compared with those in the DM group. After 4 weeks, serum TNF-a level of the
HBO group was lower than that of the DM group. D. Serum IL-6: After 2 weeks, serum IL-6 levels in the SC+HBO group were lower
than those in DM and HBO groups. After 4 weeks, serum IL-6 levels in the SC group were lower than those in the DM group. *po0.05,
**po0.01 vs DM group; WWpo0.05 vs HBO group. :po0.05, ::po0.01 vs each of the other four groups.
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potentials, and their expression of several genes encoding
extracellular and cell surface proteins may be at least twice
that reported for human bone marrow MSCs (11,17). In
comparison with bone marrow MSCs and permanent tooth
pulp stem cells, SHED exhibit a more stable expression of
genes such as basic fibroblast growth factor (bFGF) and bone
morphogenetic protein-2 (BMP-2) (18,19). In addition, the
dental pulp can be easily cryopreserved for a long time (20).
SHED can retain their potential after cryopreservation and
continue to differentiate into adult tissues after rewarming
(21). Moreover, SHED can be directly extracted and cultured
from the living dental pulp at any time.
Although the exact mechanism underlying the pancreatic
endocrine cell development is elusive, many key regula-
tory factors are known to play important roles in the
development of the pancreas. Pdx1 is a homeodomain trans-
cription factor that plays a regulatory role in early develop-
ment and cell maturation in the pancreas and maintains the
function of mature b-cells (22,23). Pdx1 acts as a transcrip-
tional master switch during pancreatic cell differentiation
(24). It binds to the TATA box of the glucose transporter 2
(GLUT2) gene and participates in its transcription (25,26).
Ngn3 serves as an important regulatory molecule involved in
the embryonic development of b-cells of the pancreas. Ngn3
initiates the differentiation of endocrine progenitor cells (27-
30) and is an important marker of islet progenitor cells
(31). Pax4 is an important transcription factor for the develop-
ment and regulation of the endocrine differentiation of the
pancreas. It promotes the expression of transcription factors
such as MafA and Nkx6.1, and induces the differentiation of
Figure 3 - Pathologic morphology of rat pancreas after 6 weeks of therapy. A. H&E staining: In the DM group, islet cells decreased and
swollen cells and cytoplasmic vacuolar changes were observed; hyaline deposits were noted under the basement membrane of some
islet capillaries, and inflammatory cells were scattered in the islets. The islet morphology in SC+HBO and SC groups was better than
that in DM group. Scale bar: 20 mm, 400. B. C. Electron microscopy of islet b-cells: In comparison with the b-cells in DM group, those
from SC+HBO and SC groups showed decreased nuclear deformation, less swollen mitochondria, reduced lipid droplet accumulation,
and significantly increased secretory granules. a. Nucleus; b. Mitochondria; c. Secretory granule; d. Ribosome. Scale bar: B.1 mm, 8000;
C. 5 mm, 2500.
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Figure 4 - Immunofluorescence analysis after 6 weeks of therapy. A. Insulin/glucagon immunofluorescence staining for pancreatic islets:
In the DM group, the distribution of glucagon-positive cells (green) in the islets was disorganized, and most cells were distributed in
the center and around the islets; glucagon-positive cells increased and insulin-positive cells (4) decreased as compared with those in NC
group. In SC+HBO and SC groups, glucagon-positive cells in the islet center decreased and insulin-positive cells increased as compared
with DM group. Scale bar: 50 mm, 200. B. MOD of insulin or glucagon immunohistochemistry in pancreatic islets: The MOD values of
insulin for SC+HBO and SC groups were higher than those for DM group. The MOD value of SC+HBO group was higher than the
values for SC and HBO groups; the MOD values of glucagon for SC+HBO and SC groups were lower than the value for DM group, while
the MOD value of SC+HBO group was lower than the values reported for SC and HBO groups. **po0.01 vs DM group; mmpo0.01 vs SC
group; WWpo0.01 vs HBO group. ::po0.01 vs each of the other four groups.
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pancreatic progenitor cells into endocrine cells, thereby enhan-
cing the transcription and biosynthesis of insulin (32). Pax4
promotes the trans-differentiation of islet a-cells into b-cells (33)
and reduces glucagon expression (34). It also facilitates the
transformation of Pdx1-positive MSCs into islet b-cells through
the regulation of the expression of Nkx6.1, MafA, and GLUT2
(35). In our study, Pdx1, Ngn3, and Pax4 gene expression in the
pancreas of SC+HBO and SC groups was significantly higher
than that in the pancreas from DM group, suggesting that
SHED may promote the transcription, differentiation, and
development of pancreatic progenitor cells at various stages
and mediate the transformation of a-cells into b-cells.
T2DM is thought to be partially associated with chronic
low-grade inflammation (36). Elevated chronic inflammatory
Figure 5 - Continued.
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factors may decrease insulin sensitivity and induce insulin
resistance, which may further impair glucose tolerance (37).
Basic research and epidemiological investigation have shown
the upregulated expression of TNF-a and IL-6 in subjects
with T2DM (38-40). Similar changes have been observed in
obese people (41). These pro-inflammatory cytokines may
cause insulin resistance by blocking insulin receptor phos-
phorylation signaling pathway and inhibiting glucose trans-
port (42,43). Cytokines such as TNF-a and IL-6 are key
factors in the initiation of inflammation and development of
insulin resistance (44,45). TNF-a infusion into healthy young
male volunteers was shown to increase serum TNF-a and IL-
6 levels and elevate HOMA-IR index, consequently inducing
insulin resistance (46). In our study, both SC+HBO and SC
groups showed significantly reduced levels of pro-inflam-
matory cytokines TNF-a and IL-6, consistent with the
improvement in inflammatory state.
Positron emission tomography (PET) experiments using
radiolabeled mouse MSCs intravenously injected in mice
showed their predominant accumulation in the lungs along
with a substantial level of (18)F-FDG elution from cells (47).
Similar results were reported by Sood (48) in 2015. The
distribution of allogeneic bone marrow-derived MSCs after
intravenous injection was pathologically and bio-optically
investigated by ex vivo imaging (using IVIS) using a fluor-
escent lipophilic tracer DiR; MSCs were found to be mainly
distributed in the lungs and liver (49). However, a study (50)
revealed the presence of BrdU-labeled MSCs in the islets
after a 45-day therapy, suggestive of their pancreatic locali-
zation. In our research, SHED were not examined or found in
the samples taken from rats after therapy; hence, it is unclear
whether the therapeutic effect of SHED was mediated by
their direct differentiation effect or secretory effect. We may
speculate that SHED play therapeutic roles through secretory
or immunoregulation effects by decreasing apoptosis and
increasing proliferation. In our study, SHED therapy could
improve the morphology of islets and b-cells, increase the
number of b-cells and level of insulin secretion, and reduce
a-cell number and glucagon secretion. The mechanism may
involve SHED-mediated upregulation in Pdx1, Pax4, and
Ngn3 gene expression that could promote pancreatic pro-
genitor cell differentiation into endocrine progenitor cells
and islet cells, induce a-cell trans-differentiation into b-cells,
and decrease the damage or apoptosis of islets by systemic or
local inflammation. Further researches are warranted to
explore the precise mechanism using optical in vivo imaging
to confirm the localization and survival conditions of SHED
in vivo or examine the cytokines secreted from SHED in vitro
or in vivo. The body weights of rats from the therapy group
increased with the remission of insulin resistance during the
experiment; hence, remission of insulin resistance was not
associated with weight loss but probably with the decrease
Figure 5 - Apoptosis and proliferation of pancreatic islet cells after 6 weeks of therapy. A. Staining for apoptosis and proliferation
analysis in islet cells: The brown cells in the islets shown by red arrows were positively stained cells. TUNEL staining showed that the
number of positively stained cells in the islets of DM group was higher than that in the islets of NC group. Positive cells in the islets of SC+
HBO and SC groups were lower than those in the islets of DM group. Ki67 and PCNA staining showed that positive cells in islets were
slightly higher in DM group than in NC group, and obviously increased in SC+HBO and SC groups as compared with those in DM
group. Scale bar: 20 mm, 400. B. Apoptosis index (AI) and proliferation index (PI) of islet cells: TUNEL AI was lower for SC+HBO and SC
groups than that for DM group. The AI for SC+HBO group was lower than that for HBO group; the PI of Ki67 and PCNA was higher for
SC+HBO and SC groups than that for DM group, while the PI of SC+HBO group was higher than that of HBO group. **po0.01 vs DM
group; WWpo0.01 vs HBO group; ::po0.01 vs each of the other four groups; %%po0.01 vs either SC or SC+HBO group.
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in TNF-a and IL-6 levels that improved the inflammatory
status. The improvement in serum lipid and urine protein
levels may also be related to the improvement in the inflam-
matory status of animals. A clinical trial (8) in 2008 showed
that the combined therapy with intrapancreatic autologous
bone marrow stem cell infusion and HBO improved the
metabolic control and reduced insulin requirements in
patients with T2DM. Another clinical trial (51) revealed the
improvement in islet functions and metabolic control with
mild adverse effects in T2DM patients subjected to auto-
logous bone marrow mononuclear cell (BM-MNC) infusion
in combination with HBO therapy; however, HBO did not
synergize with BM-MNC infusion. In our experiment, HBO
could reduce serum lipid, urinary protein, and serum pro-
inflammatory cytokine TNF-a levels, and synergistically
function with stem cells to accelerate their functions and
increase the expression of pancreatic genes, thereby showing
a tendency to increase therapeutic efficacy. The underlying
mechanism might involve its anti-inflammatory effects,
upregulation in oxidative metabolism, and improvement in
oxygen supply to local hypoxic tissues.
’ CONCLUSION
SHED in combination with HBO therapy in T2D rats could
reduce BG and HOMA-IR, increase serum insulin level,
improve serum lipid level, and reduce urine protein content.
The mechanism underlying the increase in insulin level may
be related to the SHED-mediated upregulation in the exp-
ression of Pdx1, Ngn3, and Pax4 in the pancreas, increase in
the proliferation and secretion of pancreatic islets, enhance-
ment in the trans-differentiation of a-cells into b-cells, and
decrease in the apoptosis of islet cells. Insulin resistance may
be mediated by the anti-inflammatory effects of SHED via
downregulation of TNF-a and IL-6 levels. SHED combined
with HBO therapy may exert synergistic effects.
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